Annexon, Inc. (ANNX)

NASDAQ: ANNX · IEX Real-Time Price · USD
4.620
+0.180 (4.05%)
Apr 19, 2024, 3:24 PM EDT - Market open
4.05%
Market Cap 485.50M
Revenue (ttm) n/a
Net Income (ttm) -134.24M
Shares Out 105.09M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 770,620
Open 4.330
Previous Close 4.440
Day's Range 4.280 - 4.710
52-Week Range 1.570 - 8.400
Beta 1.15
Analysts Strong Buy
Price Target 14.67 (+217.53%)
Earnings Date May 6, 2024

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in P... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 71
Stock Exchange NASDAQ
Ticker Symbol ANNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 217.53% from the latest price.

Price Target
$14.67
(217.53% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living wit...

2 days ago - GlobeNewsWire

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devast...

16 days ago - GlobeNewsWire

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a...

23 days ago - GlobeNewsWire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living wit...

4 weeks ago - GlobeNewsWire

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

BRISBANE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with ...

7 weeks ago - GlobeNewsWire

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach

Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of ...

2 months ago - GlobeNewsWire

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S.

3 months ago - GlobeNewsWire

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with ...

4 months ago - GlobeNewsWire

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

4 months ago - GlobeNewsWire

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians

4 months ago - GlobeNewsWire

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing;  Supportive Impact on Pharmacodynamic Biomarker of Complement Activity

4 months ago - GlobeNewsWire

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with...

5 months ago - GlobeNewsWire

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502

5 months ago - GlobeNewsWire

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with ...

5 months ago - GlobeNewsWire

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function in Patients with Geographic Atrophy

6 months ago - GlobeNewsWire

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS Target Enrollment Achieved in Phase 3 Pivotal Study of ANX005 in GBS Representing the Company's Third S...

6 months ago - GlobeNewsWire

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with cla...

7 months ago - GlobeNewsWire

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward

9 months ago - GlobeNewsWire

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

Additional analyses support consistent protection from vision loss Annexon to engage with regulatory agencies to determine optimal path forward for ANX007 Company to hold investor conference call on M...

9 months ago - GlobeNewsWire

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patien...

9 months ago - GlobeNewsWire

Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023

Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET

9 months ago - GlobeNewsWire

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

ARCHER data support ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection against vision loss in both foveal and non-foveal patients through ...

11 months ago - GlobeNewsWire

Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023 Initial Clinical Data Anticipated from the Phase 1b Trial of ANX009 in Lupus Nephritis in 1H'23...

1 year ago - GlobeNewsWire

Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

1 year ago - GlobeNewsWire

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023

1 year ago - GlobeNewsWire